Cyclosporine A Combined with Rituximab Successfully Treated Erythropoietin-Induced Pure Red Blood Cell Aplastic Anemia
Introduction: Erythropoietin-induced pure red blood cell aplastic anemia (EPO-PRCA) is a rare anemia, which presents a significant treatment challenge, often necessitating the cessation of erythropoiesis-stimulating agents and the adoption of immunosuppressive therapies or renal transplan...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-03-01
|
| Series: | Case Reports in Nephrology and Dialysis |
| Online Access: | https://karger.com/article/doi/10.1159/000543844 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: Erythropoietin-induced pure red blood cell aplastic anemia (EPO-PRCA) is a rare anemia, which presents a significant treatment challenge, often necessitating the cessation of erythropoiesis-stimulating agents and the adoption of immunosuppressive therapies or renal transplantation. Case Presentation: In the present case, the patient developed severe anemia after 2-year EPO treatment and was diagnosed with EPO-PRCA. The treatment with the full dose of corticosteroids and testosterone for 1 month failed to increase his hemoglobin level significantly. Therefore, the patient received the combination therapy of cyclosporine A (CsA) with rituximab, which effectively cleared the anti-EPO antibody. Then, roxadustat was given to improve renal anemia. As Hb level increased gradually, the patient was recovered from EPO-PRCA. Conclusion: This case reported an EPO-PRCA patient was successfully cured by the combination of CsA with rituximab and provided another choice for the treatment of EPO-PRCA in the future. |
|---|---|
| ISSN: | 2296-9705 |